|
Jun 23, 2021
|
Evrysdi™ Approved in Japan for the Treatment of Spinal Muscular Atrophy
- 48th country that approved Evrysdi - - First commercial sale in Japan will trigger $10M milestone payment from Roche - SOUTH PLAINFIELD, N.J. , June 23, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Evrysdi™ (risdiplam) was approved in Japan by the Japanese
|
|
|
Jun 15, 2021
|
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH PLAINFIELD, N.J. , June 15, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on June 11, 2021 it approved non-statutory stock options to purchase an aggregate of 118,350 shares of its common stock and 30,835 restricted stock units ("RSUs"), each representing the
|
|
|
Jun 11, 2021
|
Pre-symptomatic Infants with Spinal Muscular Atrophy Achieved Same Motor Milestones as Healthy Children After Treatment with Evrysdi™ in RAINBOWFISH
- JEWELFISH results demonstrated stabilization in motor function in broad SMA population - - Evrysdi has proven efficacy in adults, children and babies two months and older - - Results presented at CureSMA Conference - SOUTH PLAINFIELD, N.J. , June 11, 2021 /PRNewswire/ -- PTC Therapeutics, Inc.
|
|
|
Jun 09, 2021
|
Health and Human Services Expert Mary L. Smith Joins PTC Therapeutics' Board of Directors
SOUTH PLAINFIELD, N.J. , June 9, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the election of Mary L. Smith to the Company's Board of Directors. Ms. Smith has previously served as the Principal Deputy Director and CEO equivalent at the Indian Health Service , a $6
|
|
|
May 26, 2021
|
PTC Therapeutics Announces Orphan Drug Designations of PTC923 for the Treatment of Hyperphenylalaninemia
SOUTH PLAINFIELD, N.J. , May 26, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that both the United States Food and Drug Administration (FDA) and European Commission (EC) have granted Orphan Drug Designation (ODD) for PTC923 for the treatment of patients with
|
|
|
May 19, 2021
|
PTC Therapeutics to Participate at Upcoming Virtual Investor Conference
SOUTH PLAINFIELD, N.J. , May 19, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview at the following conference: William Blair 41 st Annual Growth Stock Conference Wednesday, June 2 nd at 3:40 p.m.
|
|
|
May 17, 2021
|
New Data Shows Devastating Impact of AADC Deficiency on Caregivers
- Caregivers spend on average 15 hours a day providing care - SOUTH PLAINFIELD, N.J. , May 17, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced data from the first study on the impact of caring for a child with the ultra-rare genetic disorder, aromatic L-Amino acid
|
|
|
May 04, 2021
|
PTC Therapeutics Provides a Corporate Update and Reports First Quarter 2021 Financial Results
- PTC518 demonstrated dose-dependent reduction of HTT mRNA in preliminary results from Phase 1 healthy volunteer trial - - Total net revenue of $118 million; 73% increase over first quarter 2020 - - DMD franchise net product revenue of $90 million; 32% increase over first quarter 2020 - - PTC has
|
|
|
Apr 27, 2021
|
PTC Therapeutics to Participate at Upcoming Virtual Investor Conferences
SOUTH PLAINFIELD, N.J. , April 27, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview at the following conferences: BofA Securities 2021 Virtual Health Care Conference Tuesday, May 11 th at 8:45 a.m.
|
|
|
Apr 20, 2021
|
PTC Therapeutics to Host Conference Call to Discuss First Quarter 2021 Financial Results
SOUTH PLAINFIELD, N.J. , April 20, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its first quarter 2021 financial results and provide an update on the company's business and outlook on Tuesday, May 4, 2021
|
|
